Molina Healthcare, Inc.
MOH
NYSE·Healthcare·Medical - Healthcare Plans·Mkt cap $10.6B
$201.75
▼ -0.43%
P/E
—
Mkt Cap
$10.6B
52-Wk Range
$121.06–$244.89
52-Week Range
$121.06 - $244.89
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 14.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized low-income healthcare focus
- Multi-state operational network
- Efficient cost management
- Strong government program relationships
Bear Case
2 risks
- Low volatility (beta 0.8).
- High premium - requires strong execution
Growth
Turning profitable
Expanding Medicaid enrollment
Value
High premium - requires strong execution
Momentum
Strong
+9.6% over 3m
Quality
Stable
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MOH right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 28, 2026
JUL 22, 2026
Reported EPS of $1.51 vs $1.39 consensus (+8.6% surprise). Revenue of $10.9B vs $10.8B expected (+0.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+8.6%
Revenue trend · last 8Q
—
+16%
+12%
+16%
+11%
+8%
-3%
-5%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$10.3B
$10.5B
$11.1B
$11.4B
$11.5B
$11.4B
$10.8B
$10.9B
Margins · last 8Q
Gross
0.0%
Operating
1.3%
Profit
0.6%
Wall Street consensus
9 analysts · 11% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
11%
Hold
78%
Sell
11%
Median Price Target
—
Latest: RBC Capital · Jul 9, 2026
vs Industry
How MOH stacks vs Medical - Healthcare Plans
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related